## **DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)** GLOBAL CLINICAL TRIAL LANDSCAPE (2024)

## **#DYK** Did you know?



DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma (NHL), accounting for 30-40% of all NHL cases worldwide



In the Asia-Pacific region, **China** reported an estimated **higher incidence** of DLBCL cases

The **United States** had the **highest estimated** number of DLBCL cases in North America

In Europe, **Germany** reported an **estimated higher incidence** of DLBCL

In ROW, **Brazil** reported the **highest incidence** of DLBCL





Marketed drugs for DLBCL, including **Rituximab** and its biosimilars, as well as **Polatuzumab Vedotin** and **Tafasitamab**, are **widely available** across the United States, Europe, and Asia



Phase III trials for Mosunetuzumab and Selinexor are progressing globally, offering promising advancements and potential new treatment options for DLBCL

## DIFFUSE LARGE B-CELL LYMPHOMA CANCER TRIAL CONTRIBUTIONS



The Asia-Pacific region shows recruitment rates comparable to those of the United States



The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com